Arbutus Biopharma Corp

-0.04 (-1.68%)
Earnings Announcements

Arbutus Reports Q3 Financial Results, Provides Corporate Update

Published: 11/09/2022 15:03 GMT
Arbutus Biopharma Corp (ABUS) - Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
Financially Strong With a Projected Cash Runway Into Q2 of 2024.
Total Revenue Was $6.0 Million for Three Months Ended September 30, 2022 Compared to $3.3 Million for Same Period in 2021.
Qtrly Loss per Share Basic and Diluted $0.12.
Q3 Earnings per Share View $-0.13, Revenue View $9.4 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $6.18 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $5.5 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.